ClinicalTrials.gg
CompletedNCT01102413Updated Dec 3, 2015Results posted

Iron Isomaltoside 1000 (Monofer®) in Non-Dialysis Dependent Chronic Kidney Disease and With Renal-Related Anaemia

A Phase 3 interventional study of Monofer and Iron Sulphate in Iron Deficiency Anemia and Chronic Kidney Disease, sponsored by Pharmacosmos A/S. Completed at 1 site in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-12-03.

Sponsored by Pharmacosmos A/S · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
351
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 32 studies testing iron isomaltoside 1000 in Anemia, Iron-Deficiency — 9 open to participants now, 9 under way, 4 of them phase 3. iron isomaltoside 1000 · Anemia, Iron-Deficiency.

Enrollment
5th of 32
351 · median 121
Started
2010
the only one that year
Phase 3
18 of 32
4 open now
Registered
3rd of 32
by date
Lead sponsor
13 of 32
Pharmacosmos A/S

Among the 32 studies testing iron isomaltoside 1000 in Anemia, Iron-Deficiency, this one is the 5th largest by enrollment, is the only one that started in 2010, is one of 18 in phase 3, and was the 3rd registered.

Anemia, Iron-Deficiency

601 studies on the registry are indexed under Anemia, Iron-Deficiency; 96 are open to participants now.

Browse Anemia, Iron-Deficiency studies →

Open to participants now

9 of the 32 studies testing iron isomaltoside 1000 in Anemia, Iron-Deficiency are open now, in 6 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About iron isomaltoside 1000

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 55 Anemia, Iron-Deficiency studies recruiting now, 19 (35%) set no upper age limit and 32 (58%) stop at 75 or younger; 16 take children under 18; 17 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies testing iron isomaltoside 1000 in Anemia, Iron-Deficiency, or all of them as a file.
02

Study summary

The study is designed to determine the effects of an investigational drug Monofer in subjects with non-dialysis dependent chronic kidney disease (NDD-CKD) subjects and with iron deficiency anaemia (IDA).

03

Conditions studied

  • Iron Deficiency Anemia
  • Chronic Kidney Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Men and women, aged more than 18 years.
  2. Subjects diagnosed with NDD-CKD with calculated eGFR between 15-59 mL/min.
  3. \< 11.0 g/dL (6.80 mmol/L)
  4. Either or both of the following iron stores indicators below target {Serum ferritin \< 100 ug/l and Transferrin saturation (TfS)\<20%}.
  5. beyond 12 months by Principal Investigator's judgement.
  6. Willingness to participate after and any authorization as required by local law ( e.g. Protected Health Information [PHI] for North America).

Exclusion criteria

Exclusion Criteria:

  1. Anaemia predominantly caused by factors other than renal impairment or iron deficiency (according to Principal Investigator's judgment).
  2. Iron overload or disturbances in utilisation of iron (e.g. haemochromatosis and haemosiderosis).
  3. Drug (i.e. previous hypersensitivity to Iron Dextran or iron mono- or disaccharide complexes or to iron sulphate or any of the study drug.
  4. Subjects with history of multiple allergies.
  5. Decompensated liver cirrhosis or active hepatitis ( (ALT) > 3 times upper normal limit).
  6. Active acute or chronic infections ((assessed by clinical judgment), supplied with White Blood Cells (WBC) and C-Reactive Protein (CRP)).
  7. Rheumatoid arthritis with symptoms or signs of active joint inflammation.
  8. Pregnancy and nursing (To avoid pregnancy, women have to be (at least 12 months must have elapsed since last menstruation), surgically sterile, or women of child bearing potential must use one of the following during the whole study period and after the study has ended for at least 5 times plasma biological half-life of the medicinal product (5 days): Contraceptive pills, intrauterine devices (IUD), contraceptive depot injections (prolonged-release gestagen), subdermal implantation, vaginal ring, and transdermal patches).
  9. Extensive active bleeding necessitating blood transfusion.
  10. Planned elective surgery during the study.
  11. Participation in any other clinical study within 3 months prior to screening.
  12. Known intolerance to oral iron treatment.
  13. Untreated B12 or folate deficiency.
  14. I.V. or oral iron treatment or blood transfusion within 4 weeks prior to screening visit.
  15. ESA treatment within 8 weeks prior to screening visit.
  16. Serum ferritin > 500 µg/L.
  17. Any other medical condition that, in the opinion of Principal Investigator, may cause the subject to be unsuitable for the completion of the study or place the subject at potential risk from being in the study or interfere with study drug evaluation. Example, Uncontrolled Hypertension, Unstable Ischemic Heart Disease or Uncontrolled Diabetes Mellitus.
  18. Body weight \< 30 kilograms.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
351 participants (actual)

Study arms

  • Experimental
    Monofer

    Injections or infusions

    Drug: Monofer

  • Active comparator
    Iron Sulphate

    Oral intake

    Drug: Iron Sulphate

Interventions

06

What researchers measure

Primary outcomes

  1. Change in Hemoglobin (Hb) Concentration From Baseline to Week 4.

    Time frame: Baseline, 4 weeks

Secondary outcomes

  1. Change in Hemoglobin Concentration From Baseline to Week 8

    Time frame: Baseline to week 8

07

Results

Posted Dec 3, 2015

Participant flow

Participant flow — Overall Study
MilestoneMonoferIron Sulphate
Started233118
Completed208106
Not completed2512

Outcome measures

PrimaryChange in Hemoglobin (Hb) Concentration From Baseline to Week 4.
Time frame:
Baseline, 4 weeks
Reported as:
Mean · g/dL
Change in Hemoglobin (Hb) Concentration From Baseline to Week 4.
g/dLMonoferIron Sulphate
Change in Hemoglobin (Hb) Concentration From Baseline to Week 4.0.57 (-3.1 to 4.0)0.35 (-3.7 to 3.9)
SecondaryChange in Hemoglobin Concentration From Baseline to Week 8
Time frame:
Baseline to week 8
Reported as:
Mean · g/dL
Change in Hemoglobin Concentration From Baseline to Week 8
g/dLMonoferIron Sulphate
Change in Hemoglobin Concentration From Baseline to Week 80.92 (-1.6 to 5.1)0.45 (-2.9 to 4.0)

Adverse events

Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Monofer—12/228 (5.3%)48/228 (21.1%)
Iron Sulphate—10/117 (8.5%)22/117 (18.8%)
Most frequent serious events
Showing 10 of 25
Most frequent serious events
EventMonoferIron Sulphate
HypersensitivityImmune system disorders2/2280/117
PneumoniaInfections and infestations2/2281/117
AnaemiaBlood and lymphatic system disorders0/2281/117
Acute left ventricular failureCardiac disorders0/2281/117
Cardiorenal syndromeCardiac disorders0/2281/117
Gastric ulcerGastrointestinal disorders0/2281/117
OesophagitisGastrointestinal disorders0/2281/117
CholangitisHepatobiliary disorders0/2281/117
Pneumonia staphylococcalInfections and infestations0/2281/117
PolyneuropathyNervous system disorders0/2281/117
Most frequent other events
Most frequent other events
EventMonoferIron Sulphate
Faeces discolouredGastrointestinal disorders0/2285/117
DiarrhoeaGastrointestinal disorders6/2284/117
PyrexiaGeneral disorders7/2284/117
NasopharyngitisInfections and infestations7/2284/117
VomitingGastrointestinal disorders6/2281/117
HyperkalaemiaMetabolism and nutrition disorders6/2280/117
HypertensionVascular disorders6/2282/117
Odema peripheralGeneral disorders5/2282/117
Back painMusculoskeletal and connective tissue disorders5/2280/117

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)MonoferIron SulphateTotal
<=18 years000
Between 18 and 65 years16480244
>=65 years6938107
Sex: Female, Male
Sex: Female, Male(Participants)MonoferIron SulphateTotal
Female14154195
Male9264156
Region of Enrollment
Region of Enrollment(participants)MonoferIron SulphateTotal
Denmark13619
Austria16521
Germany201131
United Kingdom191231
India13864202
Poland448
Russian Federation9817
Sweden101
United States13821
08

Study locations

1 site
  • Pharmacosmos
    Holbaek, Denmark
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2010, a primary completion of Jun 2014 and a completion of Jun 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2015, 1 year 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 26, 2010
First posted
Apr 13, 2010
Start
Apr 2010
Primary completionActual
Jun 2014
CompletionActual
Jun 2014
Results first posted
Dec 3, 2015
Last update
Dec 3, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 3, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01102413
Lead sponsor
Pharmacosmos A/S
Responsible party
Sponsor
First posted
Apr 13, 2010
Start date
Apr 2010
Primary completion
Jun 2014
Completion
Jun 2014
Results posted
Dec 3, 2015
Last update
Dec 3, 2015

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Iron isomaltoside 1000

Start the discussion